A Federal Adaptive, On-Demand Pharmaceutical Manufacturing Initiative
Author: Geoffrey Ling
The COVID-19 pandemic has highlighted the urgent need to address lags in American pharmaceutical manufacturing. An investment of $5 billion over five years will improve U.S. pharmaceutical manufacturing infrastructure, including the development of new technologies that will enable a responsive, end-to-end, on-demand production of up to half of the Food and Drug Administration (FDA) list of 223 essential medicines by year two, and the entire portfolio by year five. Spearheading improvements in domestic manufacturing capacity coupled with driving new adaptive, on-demand, and other advanced medicine production technologies will ensure a safe, responsive, reliable, and affordable supply of quality medicines, improving access for all citizens, including vulnerable populations living in underserved urban communities, rural areas, and tribal territories.
About the Author
Dr. Geoffrey Ling is the CEO of On Demand Pharmaceuticals, which is developing manufacturing technology for point-of-care end-to-end generic pharmaceutical production. He is a pharmacologist, neuro-intensive care physician and Professor at Johns Hopkins Hospital, former founding Director of the Biological Technologies Office at DARPA and former Assistant Director for Medical Innovation in President Obama’s Office of Science, Technology and Policy (OSTP). Dr. Ling is a retired U.S. Army colonel physician who served in both Iraq and Afghanistan. More information about Dr. Ling can be found here.